Antibodies taken from alpacas are to be used in a new pandemic flu drug, in a £33 million project led by AstraZenica.

Scinai Immunotherapeutics (NASDAQ: SCNI) , announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing P ...

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

a trispecific antibody designed as a prophylaxis and therapeutic against SARS-CoV-2 infection. Using in-house phage libraries of naïve and synthetic humanized llama nanobodies (VHH), the Ab ...

CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca ...

The separated edges of these antibodies are known as VHH antibodies, or nanobodies, which are smaller, easier to modify and more stable. The team has been working on an antibody that can work ...

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...

Screening VHH pairs creates an unbiased pool of antibodies with broader functionality, and through selection of optimal linkers even low-affinity, single-epitope binders function synergistically ...

The generic drug manufacturer was linked to the death of eight people last year, and was responsible for an outsized share of recalls for pills that didn’t dissolve properly and could harm people.

Humanization of mouse monoclonal antibodies or alpaca nanobody by genetic engineering can increase their similarity to antibodies naturally produced in humans, greatly enhancing their in vivo ...

VHH antibodies were first identified in camels in the 1980s, and they have already been used in some therapies to target chronic disease – including cancer and Alzheimer’s.